Literature DB >> 11074497

Plasma cholecystokinin levels in Prader-Willi syndrome and obese subjects.

M G Butler1, M G Carlson, D E Schmidt, I D Feurer, T Thompson.   

Abstract

The cardinal feature of individuals with Prader-Willi syndrome (PWS) is severe hyperphagia-mediated obesity resulting from a faulty satiety mechanism. PWS is the most common genetic cause of marked obesity. Cholecystokinin (CCK) is a 33-amino-acid peptide found in high levels in the gut and brain involved in mediating the satiety response to meals. Free fatty acids (FFA) are responsible for the stimulation of CCK release after a fatty meal, and CCK and plasma FFA levels rise in tandem in normal individuals. Fasting plasma CCK levels were measured by radio-immunoassay in 33 PWS subjects with a mean age of 22.2 years +/- 8.1 years and 24 obese control subjects without a known cause of their obesity with a mean age of 28.7 years +/- 12.9 years. Consistent with previous findings, neither fasting plasma FFA levels (617.5 versus 486.8 microm/mL) or CCK levels (21.0 versus 19.1 pg/mL) were significantly different in PWS or control subjects, respectively. However, there was a significant correlation between fasting plasma FFA and CCK levels in obese subjects (r = 0. 64, P < 0.01), this correlation was completely lacking in PWS subjects (r = -0.06, P = 0.79). This difference in correlation coefficients constitutes a large effect. There were no significant effects observed for genetic subtypes (15q11-q13 deletion or maternal disomy 15), body mass index, percentage of fat, plasma levels of insulin, C-peptide, glucagon or leptin, age, or gender on CCK levels in our PWS subjects. These results suggest that differences in the peripheral CCK response to FFA levels may be a factor contributing to the altered satiety response in PWS subjects. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11074497      PMCID: PMC6701931          DOI: 10.1002/1096-8628(20001106)95:1<67::aid-ajmg13>3.0.co;2-k

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  15 in total

1.  Abdominal vagal mediation of the satiety effects of exogenous and endogenous cholecystokinin in rats.

Authors:  R D Reidelberger
Journal:  Am J Physiol       Date:  1992-12

2.  Plasma cholecystokinin and pancreatic polypeptide responses after ingestion of a liquid test meal rich in medium-chain fatty acids in patients with chronic pancreatitis.

Authors:  I Nakano; A Funakoshi; H Shinozaki; K Sakai
Journal:  Am J Clin Nutr       Date:  1989-02       Impact factor: 7.045

3.  Clinical and cytogenetic survey of 39 individuals with Prader-Labhart-Willi syndrome.

Authors:  M G Butler; F J Meaney; C G Palmer
Journal:  Am J Med Genet       Date:  1986-03

Review 4.  Prader-Willi syndrome.

Authors:  S B Cassidy
Journal:  Curr Probl Pediatr       Date:  1984-01

5.  Protein meal-stimulated pancreatic polypeptide secretion in Prader-Willi syndrome of adults.

Authors:  T Tomita; G Greeley; L Watt; V Doull; R Chance
Journal:  Pancreas       Date:  1989       Impact factor: 3.327

6.  Measurement of excessive appetite and metabolic changes in Prader-Willi syndrome.

Authors:  A J Holland; J Treasure; P Coskeran; J Dallow; N Milton; E Hillhouse
Journal:  Int J Obes Relat Metab Disord       Date:  1993-09

7.  Prader-Willi syndrome: current understanding of cause and diagnosis.

Authors:  M G Butler
Journal:  Am J Med Genet       Date:  1990-03

8.  Radioimmunoassay of cholecystokinin.

Authors:  T M Chang; W Y Chey
Journal:  Dig Dis Sci       Date:  1983-05       Impact factor: 3.199

9.  Pancreatic polypeptide responses to protein meal challenges in obese but otherwise normal children and obese children with Prader-Willi syndrome.

Authors:  W B Zipf; T M O'Dorisio; S Cataland; K Dixon
Journal:  J Clin Endocrinol Metab       Date:  1983-11       Impact factor: 5.958

Review 10.  Cholecystokinin and control of food intake.

Authors:  R D Reidelberger
Journal:  J Nutr       Date:  1994-08       Impact factor: 4.798

View more
  5 in total

Review 1.  Experimental analyses of gene-brain-behavior relations: some notes on their application.

Authors:  C H Kennedy; M Caruso; T Thompson
Journal:  J Appl Behav Anal       Date:  2001

2.  Energy homeostasis in apolipoprotein AIV and cholecystokinin-deficient mice.

Authors:  Jonathan Weng; Danwen Lou; Stephen C Benoit; Natalie Coschigano; Stephen C Woods; Patrick Tso; Chunmin C Lo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-08-02       Impact factor: 3.619

3.  Hedonic eating in Prader-Willi syndrome is associated with blunted PYY secretion.

Authors:  A E Rigamonti; S Bini; F Piscitelli; A Lauritano; V Di Marzo; C Vanetti; F Agosti; A De Col; E Lucchetti; G Grugni; A Sartorio
Journal:  Food Nutr Res       Date:  2017-05-02       Impact factor: 3.894

Review 4.  Obesity management in Prader-Willi syndrome: current perspectives.

Authors:  Antonino Crinò; Danilo Fintini; Sarah Bocchini; Graziano Grugni
Journal:  Diabetes Metab Syndr Obes       Date:  2018-10-04       Impact factor: 3.168

5.  Peptide YY, cholecystokinin, insulin and ghrelin response to meal did not change, but mean serum levels of insulin is reduced in children with Prader-Willi syndrome.

Authors:  Kyung Hoon Paik; Dong-Kyu Jin; Kyung Han Lee; Lee Armstrong; Ji Eun Lee; Yoo Joung Oh; Seonwoo Kim; Eun Kyung Kwon; Yon Ho Choe
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.